Frontiers of Radiation Therapy and Oncology最新文献_第6页

Recurrence following radiotherapy. 放疗后复发。

Frontiers of Radiation Therapy and Oncology Pub Date : 2008-01-01 DOI: 10.1159/000139882

F Desgrandchamps

引用次数: 4

Hormone-refractory and metastatic prostate cancer - palliative radiotherapy. 激素难治性和转移性前列腺癌-姑息性放疗。

Frontiers of Radiation Therapy and Oncology Pub Date : 2008-01-01 DOI: 10.1159/000139886

Lutz Moser, Tina Schubert, Wolfgang Hinkelbein

{"title":"Hormone-refractory and metastatic prostate cancer - palliative radiotherapy.","authors":"Lutz Moser, Tina Schubert, Wolfgang Hinkelbein","doi":"10.1159/000139886","DOIUrl":"https://doi.org/10.1159/000139886","url":null,"abstract":"Prostate cancer progression is commonly manifested by obstructive uropathy, regional lymphatic metastases and hematogenous metastases to the axial skeleton. Radiotherapy is a mainstay in the palliation of symptomatic metastatic prostate cancer and is most often used for the palliation of painful metastatic bone lesions, resulting in a relief of pain in about 80-90% of patients and a reduction of analgesics. In metastatic disease compromising the integrity of the spinal cord or a nerve root, radiotherapy can be used as an urgent intervention to minimize neurological dysfunction and local progression or as an adjunct to surgical decompression. Local progression is often associated with hematuria, ureteric obstruction and perineal discomfort. Symptoms of metastatic lymphadenopathy like leg edema and back discomfort caused by pelvic or paraaortic metastases are related to the immediate anatomic structures affected. Radiotherapy for localized hormone-refractory prostate cancer has an excellent local control rate; nevertheless, the prognosis is poor, the majority of patients failing with distant metastasis within few years. The role of radiotherapy in hormone-refractory and metastatic prostate cancer, considering the patient's individual situation, are presented and discussed.","PeriodicalId":55140,"journal":{"name":"Frontiers of Radiation Therapy and Oncology","volume":"41 ","pages":"117-125"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000139886","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27493868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Secondary hormonal manipulation. 二次激素操纵。

Frontiers of Radiation Therapy and Oncology Pub Date : 2008-01-01 DOI: 10.1159/000139883

Axel S Merseburger, Claus Belka, Klaus Behmenburg, Arnulf Stenzl

引用次数: 5

Radical prostatectomy in the 21st century - the gold standard for localized and locally advanced prostate cancer. 21世纪根治性前列腺切除术——局部和局部晚期前列腺癌的金标准。

Frontiers of Radiation Therapy and Oncology Pub Date : 2008-01-01 DOI: 10.1159/000139873

M Schostak, K Miller, M Schrader

引用次数: 18

Combined radiotherapy and hormonal therapy in the treatment of prostate cancer. 放疗与激素联合治疗前列腺癌的疗效观察。

Frontiers of Radiation Therapy and Oncology Pub Date : 2008-01-01 DOI: 10.1159/000139875

Dirk Boehmer

引用次数: 2

Radiotherapy in biochemical recurrences after surgery for prostate cancer. 前列腺癌术后生化复发的放射治疗。

Frontiers of Radiation Therapy and Oncology Pub Date : 2008-01-01 DOI: 10.1159/000139881

Stefan Höcht, Gunnar Lohm, Lutz Moser, Wolfgang Hinkelbein

引用次数: 0

Chemotherapy in hormone-refractory prostate cancer. 激素难治性前列腺癌的化疗。

Frontiers of Radiation Therapy and Oncology Pub Date : 2008-01-01 DOI: 10.1159/000139884

Johannes Maria Wolff

引用次数: 2

Prostate cancer and active surveillance. 前列腺癌和主动监测。

Frontiers of Radiation Therapy and Oncology Pub Date : 2008-01-01 DOI: 10.1159/000139867

Per-Anders Abrahamsson

引用次数: 4

Adjuvant hormonal treatment - the bicalutamide early prostate cancer program. 辅助激素治疗-比卡鲁胺早期前列腺癌项目。

Frontiers of Radiation Therapy and Oncology Pub Date : 2008-01-01 DOI: 10.1159/000139877

Manfred P Wirth, Oliver W Hakenberg, Michael Froehner

{"title":"Adjuvant hormonal treatment - the bicalutamide early prostate cancer program.","authors":"Manfred P Wirth, Oliver W Hakenberg, Michael Froehner","doi":"10.1159/000139877","DOIUrl":"https://doi.org/10.1159/000139877","url":null,"abstract":"Several randomized trials have demonstrated that adjuvant medical or surgical castration may improve overall survival in patients with locally advanced prostate cancer undergoing external beam radiotherapy. After radical prostatectomy, patients with positive lymph nodes seem to benefit from adjuvant hormonal treatment rather than from treatment at the time of clinical progression in terms of overall survival. In patients with locally advanced, lymph node-negative prostate cancer, adjuvant hormonal treatment after radical prostatectomy has been demonstrated to delay progression without impact on survival. The Bicalutamide Early Prostate Cancer Program, the largest ongoing prostate cancer trial in the world, investigates the effect of early treatment with 150 mg bicalutamide compared with placebo as monotherapy or adjuvant treatment after radical prostatectomy or external beam radiotherapy. It demonstrated that early treatment with bicalutamide may delay objective progression of prostate cancer irrespective of primary treatment. Considering overall survival, however, there was an advantage only in the setting of external beam radiotherapy for locally advanced prostate cancer. In patients with localized disease who initially underwent watchful waiting, there was a trend to decreased survival in the arm immediately treated with bicalutamide. Altogether, there is no indication for treatment with bicalutamide in patients with localized disease.","PeriodicalId":55140,"journal":{"name":"Frontiers of Radiation Therapy and Oncology","volume":"41 ","pages":"39-48"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000139877","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27491737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Hormone therapy for prostate cancer - immediate initiation. 前列腺癌的激素治疗——即刻开始。

Frontiers of Radiation Therapy and Oncology Pub Date : 2008-01-01 DOI: 10.1159/000139878

M Schostak, K Miller, M Schrader

{"title":"Hormone therapy for prostate cancer - immediate initiation.","authors":"M Schostak, K Miller, M Schrader","doi":"10.1159/000139878","DOIUrl":"https://doi.org/10.1159/000139878","url":null,"abstract":"Although hormone therapy is widely used in the management of prostate cancer, the optimal timing of its initiation remains a matter of debate. Many studies of the last decades have reported a small but significant survival benefit and a clear delay in the development of clinical symptoms after early initiation of therapy. Patients who have localized or locally advanced prostate cancer and are not suitable for curative options like radical prostatectomy or radiotherapy can best be managed by hormone therapy alone, which has already been recognized as the optimal treatment for metastatic disease. On the other hand, long-term hormone treatment will expose the patient to the risk of substantial adverse effects, including muscle wasting, chronic fatigue and osteoporosis. Prognostic and quality-of-life factors also have an impact on the treatment decision, particularly in patients most likely to profit from an extension of the remaining life span. Based on available evidence, early hormone therapy may be recommended for men with poorly differentiated tumors or advanced disease and for those infrequently seen by their physicians. This management can prevent prostate cancer from migrating to the bones, where treatment becomes extremely difficult and cure or even longterm control of the disease is an exception.","PeriodicalId":55140,"journal":{"name":"Frontiers of Radiation Therapy and Oncology","volume":"41 ","pages":"49-57"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000139878","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27493860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4